FDMT RSI Chart
Last 7 days
12.0%
Last 30 days
-6.3%
Last 90 days
-5.1%
Trailing 12 Months
62.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 2.2M | 2.3M | 22.0M | 20.7M |
2022 | 17.3M | 2.8M | 2.0M | 3.1M |
2021 | 14.7M | 15.8M | 16.9M | 18.0M |
2020 | 8.6M | 10.3M | 12.0M | 13.6M |
2019 | 0 | 0 | 0 | 7.0M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 16, 2024 | bizily scott | sold | -45,045 | 25.74 | -1,750 | chief legal officer |
Apr 16, 2024 | bizily scott | acquired | 13,295 | 7.59714 | 1,750 | chief legal officer |
Apr 01, 2024 | bizily scott | acquired | 102,224 | 12.5383 | 8,153 | chief legal officer |
Apr 01, 2024 | bizily scott | sold | -259,102 | 31.78 | -8,153 | chief legal officer |
Mar 27, 2024 | bizily scott | acquired | 151,541 | 25.98 | 5,833 | chief legal officer |
Mar 27, 2024 | bizily scott | sold | -204,410 | 35.0438 | -5,833 | chief legal officer |
Mar 18, 2024 | bizily scott | sold | -54,722 | 31.27 | -1,750 | chief legal officer |
Mar 18, 2024 | bizily scott | acquired | 13,295 | 7.59714 | 1,750 | chief legal officer |
Feb 27, 2024 | bizily scott | sold | -57,270 | 30.00 | -1,909 | chief legal officer |
Feb 27, 2024 | bizily scott | acquired | 38,638 | 20.24 | 1,909 | chief legal officer |
Which funds bought or sold FDMT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 06, 2024 | Parallel Advisors, LLC | unchanged | - | 382 | 1,051 | -% |
May 06, 2024 | NEW YORK LIFE INVESTMENT MANAGEMENT LLC | new | - | 333,638 | 333,638 | -% |
May 06, 2024 | SG Americas Securities, LLC | reduced | -82.96 | -399,000 | 146,000 | -% |
May 06, 2024 | Candriam S.C.A. | added | 35.86 | 4,558,680 | 8,570,340 | 0.06% |
May 03, 2024 | SIGNATUREFD, LLC | added | 3.8 | 7,417 | 19,148 | -% |
May 02, 2024 | Daiwa Securities Group Inc. | reduced | -5.07 | 59,000 | 178,000 | -% |
May 02, 2024 | NISA INVESTMENT ADVISORS, LLC | added | 2.28 | 19,971 | 52,792 | -% |
May 01, 2024 | Mirae Asset Global Investments Co., Ltd. | reduced | -7.01 | -8,286 | 429,573 | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Apr 30, 2024 | Privium Fund Management B.V. | reduced | -7.96 | 271,960 | 987,660 | 0.26% |
Unveiling 4D Molecular Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to 4D Molecular Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.4B | 6.8B | -7.77 | 6.77 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.5B | 2.0B | -58.76 | 9.74 | ||||
BMRN | 15.7B | 2.5B | 76.35 | 6.35 | ||||
INCY | 12.2B | 3.8B | 16.38 | 3.24 | ||||
MID-CAP | ||||||||
APLS | 5.3B | 524.1M | -12.77 | 10.17 | ||||
BBIO | 5.2B | 107.9M | -9.51 | 48.09 | ||||
AXSM | 3.7B | 251.0M | -12.33 | 14.56 | ||||
ARWR | 3.1B | 240.7M | -10.44 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -46.38 | 3.91 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.99 | 4.48 | ||||
NVAX | 645.2M | 983.7M | -1.18 | 0.66 | ||||
CRBP | 424.2M | 881.7K | -12.56 | 481.06 | ||||
INO | 259.6M | 4.9M | -1.92 | 53.35 | ||||
IBIO | 7.1M | 2.1M | -0.26 | 2.14 |
4D Molecular Therapeutics, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Revenue | -100.0% | - | 20.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 1.00 | 0.00 | 1.00 | 15.00 | 2.00 | 5.00 | 7.00 | 4.00 | 4.00 | - |
Operating Expenses | 7.2% | 37.00 | 34.00 | 32.00 | 30.00 | 30.00 | 27.00 | 29.00 | 28.00 | 25.00 | 24.00 | 22.00 | 18.00 | 19.00 | 15.00 | 19.00 | 17.00 | - |
S&GA Expenses | 16.4% | 11.00 | 9.00 | 9.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 8.00 | 7.00 | 6.00 | 7.00 | 4.00 | 3.00 | 4.00 | - |
R&D Expenses | - | - | - | - | - | - | - | - | - | - | 16.00 | 15.00 | 13.00 | - | 12.00 | 16.00 | 13.00 | - |
Net Income | -214.8% | -32.28 | -10.26 | -29.62 | -28.68 | -27.38 | -25.69 | -28.09 | -26.34 | -25.08 | -22.24 | -7.59 | -16.41 | -20.55 | -7.83 | -15.15 | -13.16 | - |
Net Income Margin | -11.5% | -4.87* | -4.36* | -48.73* | -49.76* | -34.36* | -53.32* | -35.84* | -4.71* | -3.95* | -3.94* | -3.31* | -4.07* | -4.16* | - | - | - | - |
Free Cashflow | -1498.9% | -25.20 | -1.58 | -22.87 | -28.92 | -23.31 | -22.98 | -21.97 | -29.96 | -26.93 | -18.36 | -16.94 | -16.01 | -18.01 | - | - | - | - |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -6.0% | 340 | 362 | 353 | 244 | 262 | 280 | 303 | 325 | 353 | 241 | 255 | 270 | 288 | 58.00 |
Current Assets | -9.6% | 297 | 328 | 318 | 207 | 221 | 232 | 247 | 243 | 256 | 166 | 249 | 265 | 283 | 53.00 |
Cash Equivalents | -9.6% | 249 | 276 | 236 | 79.00 | 52.00 | 108 | 113 | 76.00 | 153 | 91.00 | 244 | 260 | 277 | 50.00 |
Net PPE | -3.0% | 20.00 | 21.00 | 21.00 | 22.00 | 22.00 | 22.00 | 21.00 | 18.00 | 14.00 | 9.00 | 6.00 | 5.00 | 5.00 | 5.00 |
Liabilities | 1.2% | 32.00 | 32.00 | 27.00 | 25.00 | 31.00 | 29.00 | 30.00 | 29.00 | 34.00 | 16.00 | 14.00 | 28.00 | 32.00 | 28.00 |
Current Liabilities | 4.3% | 19.00 | 18.00 | 14.00 | 11.00 | 16.00 | 14.00 | 14.00 | 12.00 | 16.00 | 11.00 | 10.00 | 14.00 | 17.00 | 13.00 |
Shareholder's Equity | -6.7% | 308 | 330 | 325 | 219 | 231 | 251 | 273 | 296 | 319 | 224 | 241 | 242 | 256 | - |
Retained Earnings | -8.4% | -415 | -383 | -372 | -343 | -314 | -287 | -261 | -233 | -207 | -181 | -159 | -152 | -135 | -79.03 |
Additional Paid-In Capital | 1.5% | 723 | 712 | 698 | 562 | 547 | 540 | 536 | 531 | 527 | 406 | 400 | 395 | 392 | 6.00 |
Shares Outstanding | 0.8% | 43.00 | 43.00 | 42.00 | 33.00 | 33.00 | 32.00 | 32.00 | 32.00 | 32.00 | 27.00 | 27.00 | 27.00 | - | - |
Float | - | - | - | 630 | - | - | - | 147 | - | - | - | 445 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | -2005.0% | -24,650 | -1,171 | -22,065 | -27,906 | -22,214 | -21,017 | -19,904 | -23,550 | -21,836 | -15,721 | -16,205 | -15,372 | -17,499 | -13,371 | -6,169 | -13,870 | - |
Share Based Compensation | 29.6% | 5,913 | 4,562 | 4,969 | 4,221 | 4,346 | 4,520 | 4,322 | 3,933 | 3,731 | 3,923 | 3,816 | 2,329 | 1,717 | 1,147 | 1,037 | 1,083 | - |
Cashflow From Investing | -122.3% | -6,682 | 29,981 | 49,288 | 43,130 | -35,779 | 15,371 | 57,468 | -54,110 | -32,291 | -139,010 | -737 | -642 | -508 | 349 | -120 | -721 | - |
Cashflow From Financing | -54.9% | 4,762 | 10,557 | 130,519 | 10,994 | 2,046 | 460 | -50.00 | 629 | 116,139 | 1,977 | 820 | -847 | 205,978 | 900 | 72,494 | -389 | - |
Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue: | ||
Collaboration and license revenue | $ 20,723 | $ 3,129 |
Operating expenses: | ||
Research and development (includes $183 and $306 for the years ended December 31, 2023 and 2022, respectively, attributable to related parties) | 97,096 | 80,253 |
General and administrative | 36,494 | 32,908 |
Total operating expenses | 133,590 | 113,161 |
Loss from operations | (112,867) | (110,032) |
Other income (expense): | ||
Interest income | 12,211 | 2,573 |
Other expense, net | (181) | (35) |
Total other income (expense), net | 12,030 | 2,538 |
Net loss | $ (100,837) | $ (107,494) |
Net loss per share, basic | $ (2.58) | $ (3.32) |
Net loss per share, diluted | $ (2.58) | $ (3.32) |
Weighted-average shares outstanding used in computing net loss per share, basic | 39,130,067 | 32,351,221 |
Weighted-average shares outstanding used in computing net loss per share, diluted | 39,130,067 | 32,351,221 |
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 249,108 | $ 52,351 |
Marketable securities | 39,124 | 161,203 |
Prepaid expenses and other current assets | 8,356 | 6,957 |
Total current assets | 296,588 | 220,511 |
Marketable securities, long-term | 10,954 | 4,908 |
Property and equipment, net | 20,126 | 22,262 |
Operating lease right-of-use assets, net | 11,539 | 13,085 |
Other assets | 684 | 1,080 |
Total assets | 339,891 | 261,846 |
Current liabilities | ||
Accounts payable | 3,515 | 3,322 |
Accrued and other current liabilities | 12,014 | 8,870 |
Deferred revenue | 273 | 884 |
Operating lease liabilities, current portion | 3,149 | 2,655 |
Total current liabilities | 18,951 | 15,731 |
Deferred revenue, net of current portion | 972 | 1,076 |
Derivative liability | 369 | 212 |
Operating lease liabilities, long-term portion | 11,522 | 13,469 |
Other liabilities | 248 | 21 |
Total liabilities | 32,062 | 30,509 |
Commitments and contingencies (Note 9) | ||
Stockholders' equity | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022 | 0 | 0 |
Common stock, $0.0001 par value, 300,000,000 shares authorized at December 31, 2023 and 2022; 43,075,218 and 32,626,627 shares issued and outstanding at December 31, 2023 and 2022, respectively | 4 | 3 |
Additional paid-in-capital | 723,136 | 547,020 |
Accumulated other comprehensive gain (loss) | 16 | (1,196) |
Accumulated deficit | (415,327) | (314,490) |
Total stockholders' equity | 307,829 | 231,337 |
Total liabilities and stockholders' equity | $ 339,891 | $ 261,846 |